



Biotech Daily

Friday August 1, 2014

Daily news on ASX-listed biotechnology companies

- * JULY BDI-40 UP 4%, ASX200 UP 4%, BIG CAPS UP 1.5%
- ACRUX UP 83%, IMPEDIMED UP 64%, GI DYNAMICS DOWN 27%
- * TODAY: ASX, BIOTECH DOWN: ALCHEMIA UP 4%, USCOM DOWN 18%
- * RESMED RECORD REVENUE, PROFIT
- * DANISH APPROVAL FOR PSIVIDA'S ILUVIEN FOR DME
- * MEDIGARD CHINA PARTNER TAKES \$300k CONVERTIBLE NOTE

MARKET REPORT

The Australian stock market fell 1.36 percent on Friday August 1, 2014 with the S&P ASX 200 down 76.5 points to 5,556.4 points.

Seven of the Biotech Daily Top 40 stocks were up, 22 fell, seven traded unchanged and four were untraded.

Alchemia was the best, up two cents or 3.54 percent to 58.5 cents with 103,723 shares traded, followed by Tissue Therapies up 3.51 percent to 29.5 cents with 23,500 shares traded.

Both Anteo and Cellmid climbed 3.45 percent; with Bionomics and Ellex up by more than one percent.

Uscom led the falls, down 4.5 cents or 18.4 percent to 20 cents with 2,000 shares traded, followed by Compumedics down 13.8 percent to 12.5 cents with 40,000 shares traded.

Circadian and Pharmaxis lost more than 10 percent; Acrux fell 9.3 percent; Patrys was down 6.9 percent; Universal Biosensors and Resmed fell more than five percent; Avita, Biotron, Neuren and Starpharma fell more than four percent; CSL, Genetic Technologies, Nanosonics and Oncosil were down more than three percent; Analytica, GI Dynamics and Prima shed more than two percent; Benitec, Impedimed, Prana and Sirtex lost one percent or more; with Mesoblast down 0.2 percent.

BIOTECH DAILY TOP 40 INDEX (BDI-40)

The Biotech Daily Top-40 Index (BDI-40) was up 4.0 percent in July, in line with the S&P ASX200 up 4.4 percent, with 20 companies up, 15 down and five unchanged.

Acrux's rebound on continued Axiron sales added \$139 million to the index and Sirtex improved by \$120 million - more than offsetting the \$74 million fall by GI Dynamics and Mesoblast's \$65 million drop.

For the 12 months to July 31, 2014, the ASX200 was up 11.5 percent, with the BDI-40 down 6.3 percent, adjusted for the removal of the then \$1,365 million Heartware.

The three Big Caps (which are not included in the BDI-40) were up a cumulative 1.5 percent in July, but down 0.4 percent for the year to July 31, with Cochlear up 3.15 percent in July, CSL up 1.6 percent and Resmed up 0.5 percent.


Acrux was July's best, up 83.2 percent to \$306 million, followed by Impedimed up 63.6 percent to \$72 million, IDT (40%), Starpharma (30.3%), Oncosil (27.8%), Neuren (27.1%), Clinuvel (26.3%), Phosphagenics (16.85%), Prana (15.7%) and Psivida (13.7%).

GI Dynamics had the deepest fall in July, down 26.9 percent to \$201 million, followed by Anteo retreating a further \$37 million or 23.4 percent to \$121 million, Analytica (17.1%), Osprey (13.0%), Benitec (12.9%), Bionomics (10.9%) and Medical Developments (9.2%).

Outside the BDI-40, Calzada was the only significant rise, up 13.6 percent for the month and up 66.7 percent for the year to \$50 million, while Progen tumbled 72.7 percent to \$12 million on the failure of the Medigen licenced PI-88 for live cancer.

On the Nasdaq, Biota continued a weak recovery, up 14.15 percent to \$121 million, Heartware slipped a further 3.6 percent to \$1,538 million, Sunshine Heart lost 10 percent to \$90 million, while the Canadian Bioniche climbed 91.7 percent to \$46 million.

BDI-40 v ASX200 Jun 30, 2006 to Jul 31, 2014 - Adjusted



RESMED

Resmed has posted record revenue of \$US1,554.973,000 up 2.7 percent and net profit after tax up 12.4 percent to \$US345,273,000 million for the 12 months to June 30, 2014. Resmed chief executive officer Mick Farrell said that the "fourth quarter results were lower than anticipated, the result of softer sales in the Americas, partially offset by good growth in our international markets".

"We continue to benefit from our globally diversified business, with constant currency revenue growth of five percent in our combined Europe and Asia-Pacific businesses," Mr Farrell said.

Resmed said diluted earnings per share was \$US2.39, a 13.8 percent increase over the 12 months to June 30, 2013.

Resmed said research and development expenditure for the year was down 1.6 percent to \$US118,226,000, or 7.6 percent of revenue.

Resmed said it would pay a dividend for the three months to June 30, 2014 of 28 US cents a share, with a record date of August 21, to be paid on September 18, 2014.

Resmed fell 28 cents or 5.1 percent to \$5.23 with 18.8 million shares traded.

PSIVIDA

Psivida says that the Danish Health and Medicines Authority has granted marketing authorization for Iluvien for with chronic diabetic macular oedema.

Psivida said that the authorization for vision impairment associated with chronic diabetic macular oedema considered insufficiently responsive to available therapies had been approved in nine European Union countries including Austria, Denmark, France, Germany, Italy, Norway, Portugal, Spain and the UK and was commercially available in the UK and Germany.

The company said that Iluvien was pending approval, in eight more EU countries, Belgium, the Czech Republic, Finland, Ireland, Luxembourg, the Netherlands, Poland and Sweden, following the successful completion of the mutual recognition procedure.

Psivida said that Iluvien was under review by the US Food and Drug Administration with a Prescription Drug User Fee Act (PDUFA) goal date of September 26, 2014.

Psivida chief executive officer Dr Paul Ashton said that the company was entitled to a \$US25 million milestone payment from licensee Alimera Sciences on FDA approval of Iluvien as well as a share of net profits from Alimera's sales of Iluvien on a country-by-country basis including in the EU and the US.

Psivida was untraded at \$4.80.

MEDIGARD

Medigard says it has secured \$300,000 in debt funding through a convertible note with partner the China-based Shanghai Sol-Millennium Medical Products Co.

Medigard said that the funds would be used for working capital, including patent costs and further product development.

The company said that the notes had a maturity date of 36 months from issue and were to be drawn periodically from July 31, 2014 until February 23, 2015 and had an interest rate of eight percent per annum.

Medigard said that Shanghai Sol-Millennium signed a licence for the manufacture and distribution of the Medigard blood collection device and the blood flash needle in March 2013 (BD: Feb 2, 2011).

Medigard was untraded at two cents.

BIOTECH DAILY'S TOP 40 WITH MARKET CAPITALIZATION

Company \$Am	Aug-13	Jul-14	Aug-14
Cochlear	3,484	3,521	3,632
CSL	32,182	31,667	32,177
Resmed	8,030	7,688	7,730
BDI-20			
Acrux	561	167	306
Alchemia	120	180	183
Admedus	55	195	180
Benitec	24	132	115
Bionomics	226	230	205
Biotron	19	24	27
Clinuvel	73	72	91
GI Dynamics	259	275	201
Impedimed	27	44	72
Mesoblast	1,852	1,438	1,373
Nanosonics	194	208	221
Neuren	120	129	164
Osprey	54	69	60
Pharmaxis	51	20	21
Prima	122	49	49
Psivida	92	124	141
Sirtex	699	947	1,067
Tissue Therapies	49	78	75
Universal Biosensors	131	35	32
Viralytics	26	50	50
Second 20			
Analytica	11	35	29
Anteo	44	158	121
Antisense	26	20	19
Atcor	16	15	16
Avita	44	33	34
Cellmid	18	19	21
Circadian	11	9	9
Compumedics	12	24	24
Ellex	21	40	39
Genetic Technologies	40	22	21
IDT	13	15	21
Living Cell	19	18	18
Medical Developments	79	76	69
Oncosil	25	36	46
Optiscan	12	5	6
Patrys	21	21	20
Phosphagenics	107	89	104
Prana	145	108	125
Starpharma	275	165	215
Uscom	12	18	20

* Biotech Daily editor, David Langsam, owns shares in Acrux, Alchemia, Allied Health, Benitec, Biota, Mesoblast, Nanosonics, Neuren and non-biotechnology stocks. Through Australian Ethical Superannuation he has an indirect interest in Acrux, Alchemia, Atcor, Avita, Circadian, Cochlear, CSL, Ellex, IDT, Neuren, Pharmaxis, Prana, Resmed, Sirtex and Universal Biosensors. These holdings are liable to change.

Biotech Daily can be contacted at: PO Box 5000, Carlton, Victoria, Australia, 3053
email: editor@biotechdaily.com.au; www.biotechdaily.com.au; twitter: @biotech_daily